Chiang Mai University researchers have isolated a plant-derived compound that demonstrates potent anti-cancer effects against human lymphoma cells in laboratory tests, adding to Thailand's growing body of natural compound oncology research. The molecule, called dicentrine, is an alkaloid extracted from the vine Stephania venosa, and according to a study released August 3, it kills malignant lymphocytes with notable selectivity while largely sparing healthy immune cells.
Why This Matters
• Targeted toxicity: Dicentrine killed Ramos lymphoma cells at concentrations of just 5.16 µg/mL, showing less harm to normal blood cells—a critical advantage over conventional chemotherapy.
• Multi-pathway attack: The compound simultaneously shuts down cell proliferation, arrests the cancer growth cycle, and triggers programmed cell death (apoptosis) in lymphoma tissue.
• Local innovation: The research reinforces Thailand's growing reputation in pharmaceutical bioprospecting and positions Chiang Mai University as a regional hub for cancer drug discovery.
The Science Behind the Discovery
The Cancer Research Unit of Associated Medical Sciences (AMS CRU) at Chiang Mai University conducted molecular pharmacological characterization of dicentrine using two standard human lymphoma cell lines—Raji and Ramos—both derived from Burkitt lymphoma, an aggressive B-cell malignancy. The compound demonstrated cytotoxic concentrations (IC50 values) of 9.03 µg/mL for Raji cells and 5.16 µg/mL for Ramos cells, meaning those doses reduced viable cancer cells by 50%.
What distinguished dicentrine from blunt-force chemotherapy agents was its selectivity index. When tested against peripheral blood mononuclear cells (PBMCs)—the white blood cells that comprise much of the body's immune defense—the alkaloid exhibited far lower toxicity. This therapeutic window is a foundational requirement for any candidate drug, as it suggests the compound could attack tumors without crippling the patient's immune system.
At the molecular level, dicentrine worked through a cascade of mechanisms. It suppressed c-Myc expression, a notorious oncogene that drives uncontrolled proliferation in Burkitt lymphoma and other blood cancers. The compound also reduced phosphorylated c-Myc, the activated form of the protein. Western blot analysis revealed that dicentrine substantially lowered total Akt protein expression, a key node in the PI3K/Akt signaling pathway—one of the most frequently hyperactivated pathways in human cancers.
Network pharmacology modeling and molecular docking simulations indicated strong binding affinities for PI3K, Akt, caspase-3, and caspase-9, all pivotal enzymes in cell survival and death pathways. By inhibiting PI3K/Akt signaling, dicentrine essentially cuts off the cancer cell's survival instructions. By binding caspases, it activates the cell's self-destruct machinery.
Cell Cycle Arrest and Programmed Death
Flow cytometry data showed that dicentrine induced G0/G1 arrest in Raji cells and G2/M arrest in Ramos cells, meaning the compound halted the cancer cells at different checkpoints in their replication cycle. This arrest prevented the cells from dividing and spreading. Simultaneously, the compound increased Annexin V-positive populations—a hallmark of early apoptosis—and elevated levels of cleaved caspase-3, the executioner enzyme that dismantles the cell from within.
The dose-dependent effect means that as researchers increased the concentration of dicentrine, the number of viable lymphoma cells dropped proportionally. This predictable relationship is another positive signal for drug development, as it suggests the compound can be titrated to achieve therapeutic effects without unnecessary toxicity.
What This Means for Residents
For patients and families in Thailand dealing with lymphoma diagnoses, this research is a long-term signal of hope rather than an immediate treatment option. Dicentrine has not entered clinical trials in humans, and no regulatory body—including the U.S. Food and Drug Administration (FDA) or Thailand's Food and Drug Administration—has approved it for therapeutic use. The timeline from laboratory discovery to bedside treatment typically spans 10 to 15 years, assuming the compound survives successive phases of safety and efficacy testing. This research does not affect current lymphoma treatment decisions, which should remain guided by established clinical protocols and specialist recommendations.
Residents interested in following this research can monitor announcements from Chiang Mai University's Faculty of Associated Medical Sciences or the institutional website.
Still, the findings matter for several reasons. First, they validate Thailand's investment in pharmaceutical sciences and indigenous bioprospecting. Stephania venosa is native to Southeast Asia, and the ability to discover, isolate, and characterize bioactive compounds from regional flora strengthens the country's intellectual property portfolio and positions Thai institutions as collaborators—not just consumers—in global drug development.
Second, the research underscores the potential of natural product chemistry in oncology. While modern cancer therapy has gravitated toward synthetic small molecules and monoclonal antibodies, plant-derived alkaloids remain a proven source of effective drugs. Vincristine and vinblastine, both isolated from the Madagascar periwinkle, have been frontline lymphoma treatments for decades.
Third, the study's emphasis on selectivity addresses one of the most punishing aspects of chemotherapy: collateral damage to healthy cells. If dicentrine or a derivative eventually advances to clinical testing, its favorable toxicity profile could translate to fewer side effects, improved quality of life, and better treatment adherence.
The Road Ahead
No clinical trial registry currently lists dicentrine as an investigational agent for lymphoma. The Chiang Mai University team's work remains in the preclinical domain, focused on elucidating molecular mechanisms in cell culture and, potentially, animal models. The next logical step would be toxicology studies in mice or rats to establish safe dosing ranges, followed by pharmacokinetics research to understand how the compound is absorbed, distributed, metabolized, and excreted.
If those studies yield positive results, a Phase 1 clinical trial in humans could assess safety and tolerability in a small cohort of patients with refractory lymphoma—those who have exhausted standard treatments. Phase 2 would evaluate efficacy in a larger group, and Phase 3 would compare dicentrine against existing therapies in randomized, controlled trials. Only after successful completion of all three phases could a pharmaceutical sponsor apply for regulatory approval.
The Thailand pharmaceutical sector has limited experience bringing novel oncology drugs through this gauntlet. Most cancer drugs prescribed in the country are imported or manufactured under license. However, the government has signaled interest in boosting domestic drug innovation through grants, tax incentives, and public-private partnerships. If dicentrine proves viable, it could become a flagship project for Thailand's ambition to move up the value chain in biopharmaceuticals.
Institutional Collaboration and Capacity
The dicentrine study was a collaborative effort involving the Department of Chemistry, Department of Medical Technology, Department of Pharmaceutical Sciences, and the Center of Excellence in Pharmaceutical Nanotechnology at Chiang Mai University. This cross-disciplinary structure is critical for modern drug discovery, which requires expertise in botany, organic chemistry, cell biology, pharmacology, and computational modeling.
While the current research appears to be domestically led, Chiang Mai University maintains international partnerships with institutions such as the University of Minnesota, the London School of Hygiene & Tropical Medicine, and Queen Mary University of London in areas spanning global health, tropical medicine, and health sustainability. The LUCENT International Collaboration at the Faculty of Associated Medical Sciences also facilitates joint projects with foreign laboratories. These networks could prove valuable if dicentrine advances to stages requiring specialized expertise or funding.
Context: Lymphoma in Thailand
Lymphoma encompasses a diverse group of blood cancers that originate in the lymphatic system. According to the Thailand National Cancer Institute, non-Hodgkin lymphoma is among the top 10 most common cancers in the country, with incidence rates rising steadily over the past two decades. Burkitt lymphoma, the subtype targeted in this study, is relatively rare but highly aggressive, often requiring intensive chemotherapy regimens such as R-CHOP or GDP protocols.
Current treatment options in Thailand include chemotherapy, radiation, stem cell transplantation, and increasingly, targeted therapies such as rituximab (a monoclonal antibody) and small-molecule inhibitors of Bruton tyrosine kinase or PI3K. While these treatments have improved survival rates, they come with significant toxicity, cost, and accessibility challenges—particularly outside Bangkok. A well-tolerated, plant-derived drug manufactured domestically could ease both financial and logistical burdens on patients and the healthcare system.
The Chiang Mai University discovery is a proof of concept, not a cure. But it demonstrates that Thailand possesses the scientific infrastructure and botanical resources to contribute meaningfully to global cancer research. For residents, the takeaway is patience tempered with optimism: the compound shows promise, the science is solid, and the institution is credible. Whether dicentrine advances to clinical trials will depend on securing funding, regulatory pathways, and commercial partners.
